Pharma: Page 62
-
Permission granted by IQVIA
Sponsored by IQVIAFinding the right mix: Digital transformation offers opportunities for improved HCP engagement
Field teams and HCPs alike are learning how digital, data-driven approaches can best support safe, productive engagement.
Nov. 9, 2020 -
Permission granted by Novartis
Novartis rare disease drug, repurposed for COVID-19, fails in late-stage study
The Swiss drugmaker's COVID-19 research efforts now largely rest on the outcome of a recent alliance to develop oral medicines for the new coronavirus.
By Ben Fidler • Nov. 6, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Who would get Regeneron's COVID-19 antibody treatment?
The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection. Fast antibody testing, however, is spotty.
By Jonathan Gardner • Nov. 5, 2020 -
Jacob Bell/BioPharma Dive
Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround.
By Ben Fidler • Nov. 5, 2020 -
Permission granted by Bristol-Myers Squibb
Bristol Myers bet pays off as psoriasis drug beats Amgen rival in study
While full data were not disclosed, the trial's outcome signals competition for Amgen's Otezla, which Celgene was forced to divest last year as a result of its acquisition by Bristol Myers.
By Ned Pagliarulo • Nov. 3, 2020 -
Courtesy of Eli Lilly
US to pay Lilly $375M for supply of COVID-19 drug
Lilly has asked the FDA for emergency approval of the antibody-based treatment, but scaling up production will take time.
By Ned Pagliarulo • Oct. 28, 2020 -
Sanofi, GSK pledge 200M doses to an international coronavirus vaccine alliance
The two drugmakers are aiding an international effort to ensure low- and middle-income countries can get access to successful coronavirus shots.
By Kristin Jensen • Oct. 28, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study
The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19.
By Ben Fidler • Updated Oct. 27, 2020 -
Getty Images
Sponsored by SAPRegulatory-driven material control with SAP
Learn about material segmentation, a unique approach for characteristics-based planning and execution.
By Stephen Cloughley, Senior Director, SAP Life Sciences IBU • Oct. 26, 2020 -
Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales
Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.
By Jacob Bell • Oct. 21, 2020 -
Sponsored by ZS
Patients and physicians brace for flu season amid COVID-19
ZS surveyed more than 500 patients and 500 physicians to gather their perspectives on COVID-19's potential impact on flu vaccination rates.
Oct. 21, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
J&J halts studies of coronavirus vaccine due to participant's illness
The company did not disclose details, nor could it confirm whether the participant had received its shot. But J&J is now the second vaccine developer, along with AstraZeneca, to suspend testing for a safety review.
By Ned Pagliarulo • Updated Oct. 13, 2020 -
Getty Images
Mallinckrodt, beset by opioid drug suits, files for bankruptcy
The drugmaker aims to resolve billions of dollars in opioid-related claims and a federal lawsuit over Medicaid rebates, liabilities it says would be "otherwise unmanageable."
By Ned Pagliarulo • Oct. 12, 2020 -
Ewa Krawczyk, National Cancer Institute
Pfizer stumbles again in early breast cancer study, clearing path for Eli Lilly
The latest setback for Pfizer's top-selling Ibrance leaves Lilly's Verzenio, for now, as the only drug in its class to be proven to stave off breast cancer recurrence after surgery.
By Ben Fidler • Oct. 9, 2020 -
Merck research chief Roger Perlmutter to retire, leaving immunotherapy legacy
Under his leadership, Merck developed a once overlooked cancer drug into Keytruda, now a top-selling medicine and foundational treatment for more than a dozen types of tumors.
By Ned Pagliarulo • Oct. 2, 2020 -
AstraZeneca restarts another coronavirus vaccine trial, but US delay lingers
The company is now cleared to resume testing of its experimental shot in multiple countries, but a Phase 3 trial in the U.S. remains halted as an FDA investigation reportedly widens.
By Ben Fidler • Oct. 2, 2020 -
Pfizer pushes deeper into China with stake in cancer biotech
The $200 million investment in CStone Pharmaceuticals puts Pfizer in charge of selling a cancer immunotherapy in the world's second largest drug market.
By Jacob Bell • Sept. 30, 2020 -
Ironwood lays off one-third of staff after heartburn drug falls short in study
The company will halt further work on its only fully owned drug and focus instead on expanding sales of its marketed product Linzess.
By Jonathan Gardner • Updated Sept. 29, 2020 -
Boghosian, Joyce. (2020). "President Trump meets with the Coronavirus Task Force" [Photograph]. Retrieved from Flickr.
Trump forges ahead with drug import plan, but impact in doubt
Under the proposed plan, states would be permitted to import lower-priced products from Canada and drugmakers from around the globe. But participation is uncertain, as is the plan's effect on drug prices.
By Jonathan Gardner • Sept. 25, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
J&J begins largest Phase 3 study of a coronavirus vaccine
The trial, which launched Wednesday in the U.S., South Africa and several South American countries, will enroll as many as 60,000 participants.
By Ned Pagliarulo • Sept. 23, 2020 -
Permission granted by Novartis
FDA sets back Novartis plans to expand use of SMA gene therapy
The agency has asked the company to run a new study of the Zolgensma formulation that it aims to bring to older patients with spinal muscular atrophy.
By Ben Fidler • Sept. 23, 2020 -
FDA decision on Bristol Myers cell therapy could come down to the wire
An FDA decision on Bristol Myers' myeloma treatment ide-cel could come four days before a key deadline related to the pharma's buyout of Celgene.
By Jonathan Gardner • Sept. 22, 2020 -
Ewa Krawczyk, National Cancer Institute
With Eli Lilly data, another drug emerges to stop breast cancers from returning
The highly anticipated results could change how some patients with the most common form of breast cancer are treated — and drive up the costs of care.
By Ben Fidler • Sept. 20, 2020 -
Kendall Davis/BioPharma Dive
Arrowhead shares soar on liver disease data from four patients
Encouraged by the early study results, Arrowhead plans to ask regulators to streamline its clinical trials, which could pressure rivals Vertex and Dicerna.
By Jonathan Gardner • Sept. 16, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly offers first evidence that its antibody drug may help treat COVID-19
The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear.
By Ben Fidler • Sept. 16, 2020
Previous
